Home › Propionic Acidemia › NCT05130437

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

Who can join

Ages 1 and older · All sexes

Inclusion Criteria:

* Participated in Study mRNA-3927-P101.
* Completed the EOT/ET visit in Study mRNA-3927-P101 and enroll in this study such that the first dose in this study is planned to be within 14±3 days of the last dose of mRNA-3927 in the mRNA-3927-P101 study.

Exclusion Criteria:

* Not expected to receive clinical benefit from continued mRNA-3927 administration, in the opinion of the Investigator.
* Any clinical or laboratory abnormality or medical condition that, at the discretion of the Investigator, may put the individual at increased risk by participating in this study.
* History of liver and/or kidney transplant.

About the study

The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).

What is being tested

• mRNA-3927 (biological)

Sponsor: ModernaTX, Inc. · Participants: 50 · Started: Nov 9, 2021

Contact the study team

• Moderna WeCare Team · Phone: 1-866-663-3762

Official record on ClinicalTrials.gov — NCT05130437

Locations in the U.S.

Conditions

• Propionic Acidemia
• Inborn Errors Metabolism
• Genetic Disorders
• Acidosis
• Metabolic Disorders

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.